Literature DB >> 12902800

An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score.

Andrew Carr1, Matthew Law.   

Abstract

HIV lipodystrophy can be objectively diagnosed using a score derived from the 10 parameters in the HIV lipodystrophy case definition (LDCD). Lipodystrophy severity remains subjectively determined by physical examination and patient assessment. Regional dual-energy x-ray absorptiometry (DEXA) and single-slice abdominal computed tomography (CT) scanning are objective but are gender-dependent body composition measures. The LDCD score may provide a means of generating an objective and lipodystrophy grading/severity scale applicable to both men and women. Total and regional clinical lipodystrophy severity scores (generated using the HIV Outpatient Study [HOPS] scale: nil (0), mild (1), moderate (2), and severe (3) lipoatrophy or fat accumulation in 8 body regions) were correlated with objective measures of LD (LDCD score, DEXA, abdominal CT) and metabolic (lipid, glycemic, acid-base) parameters known to correlate significantly with lipodystrophy severity. Analysis was based on 417 lipodystrophic adults and 371 controls recruited to the HIV LDCD study. Correlation coefficients were used to compare physician and patient assessments (rPhysician, rPatient) with objective LD measures and metabolic parameters. The strongest objective correlate of total clinical lipodystrophy severity was the LDCD score (rPhysician = 0.641 [95% CI, 0.584-0.698]; rPatient = 0.620 [95% CI, 0.561-0.678]), whereas the strongest imaging correlate (trunk:limb fat ratio on DEXA) was significantly lower (rPhysician = 0.483 [95% CI, 0.420-0.546]; rPatient = 0.475 [95% CI, 0.412-0.538]; P < 0.001). The LDCD score also yielded significantly greater correlations with 7 of the 8 metabolic parameters than did clinical lipodystrophy severity scores. Based on quartiles of physician-rated severity, the LDCD scores were categorized to allow for rating of lipodystrophy as absent (LDCD score < 0), grade 1 (0-9.9), grade 2 (10-14.9), grade 3 (15-22.9), and grade 4 (>or=23). In conclusion, the LDCD score is the best objective measure of lipodystrophy severity and, in contrast to DEXA and CT, it is also gender independent. Subjective assessment of lipodystrophy severity could possibly be abandoned in cross-sectional studies. The LDCD score and its derived lipodystrophy grading scale merit prospective evaluation.

Entities:  

Mesh:

Year:  2003        PMID: 12902800     DOI: 10.1097/00126334-200308150-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  19 in total

1.  Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.

Authors:  Richard K Sterling; Wendy C King; Abdus S Wahed; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Authors:  Richard K Sterling; Abdus S Wahed; Wendy C King; David E Kleiner; Mandana Khalili; Mark Sulkowski; Raymond T Chung; Mamta K Jain; Mauricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2019-05       Impact factor: 10.864

3.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

Review 4.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

5.  Lipodystrophy and metabolic complications of highly active antiretroviral therapy.

Authors:  Ankit Parakh; Anand Prakash Dubey; Ajay Kumar; Anshu Maheshwari
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

6.  Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.

Authors:  Marisa Tungsiripat; Mary Ann O'Riordan; Norma Storer; Danielle Harrill; Jason Ganz; Daniel Libutti; Mariana Gerschenson; Grace A McComsey
Journal:  HIV Clin Trials       Date:  2009 Sep-Oct

7.  Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

Authors:  Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens
Journal:  AIDS Res Ther       Date:  2010-07-14       Impact factor: 2.250

8.  Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Susan L Rosenkranz; Kevin E Yarasheski; Michael F Para; Richard C Reichman; Gene D Morse
Journal:  Metab Syndr Relat Disord       Date:  2007-06       Impact factor: 1.894

9.  Severity of lipodystrophy is associated with decreased health-related quality of life.

Authors:  Giovanni Guaraldi; Rita Murri; Gabriella Orlando; Chiara Giovanardi; Nicola Squillace; Marcella Vandelli; Barbara Beghetto; Giulia Nardini; Maria De Paola; Roberto Esposito; Albert W Wu
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078

10.  Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy.

Authors:  M Massella; J Ivanovic; R Bellagamba; R De Vita; L Fracasso; V Tozzi; V Fragola; M Rizzica; P Narciso
Journal:  Patient Prefer Adherence       Date:  2011-05-17       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.